Optimization of Small Molecule GPR17 Antagonists for Multiple Sclerosis
多发性硬化症小分子 GPR17 拮抗剂的优化
基本信息
- 批准号:10369692
- 负责人:
- 金额:$ 10.97万
- 依托单位:
- 依托单位国家:美国
- 项目类别:
- 财政年份:2021
- 资助国家:美国
- 起止时间:2021-03-15 至 2024-02-29
- 项目状态:已结题
- 来源:
- 关键词:AblationAdverse effectsAgonistAutoimmuneBiological AssayBiologyBrainCell Differentiation processChemistryChronicCollaborationsComplementComputer AnalysisDataDemyelinating DiseasesDemyelinationsDendritesDevelopmentDiseaseDisease ProgressionEnsureEvaluationExhibitsExperimental Autoimmune EncephalomyelitisFinancial compensationFrequenciesG-Protein-Coupled ReceptorsGPR17 geneGoalsHomology ModelingImmune responseImmunomodulatorsImmunosuppressive AgentsImpairmentIn VitroIon ChannelKnockout MiceLeadLigandsLiteratureMediatingMetabolicModelingModificationMultiple SclerosisMusMyelinMyelin Basic ProteinsMyelin SheathNational Institute of Mental HealthNeural ConductionNeurologicNeuronsOligodendrogliaOrphanPeripheralPermeabilityPharmaceutical PreparationsPharmacologyPharmacology StudyPharmacotherapyPlayProcessPropertyPsychotropic DrugsRattusRelapseReportingRoleSeriesSeveritiesSignal TransductionSolubilitySystemTechniquesTherapeuticUp-RegulationValidationWorkanalogantagonistaxonal degenerationbaseblood-brain barrier permeabilizationdesigndisabilitydrug discoveryimprovedin silicoin vivomouse modelmyelinationnervous system disordernew therapeutic targetnovelnovel therapeuticsoligodendrocyte precursoroverexpressionpharmacophoreprecursor cellprogramsreceptorrelease of sequestered calcium ion into cytoplasmremyelinationrepairedscaffoldscreening programsmall moleculetherapeutic targettool
项目摘要
Project Summary: The goal of this R03 proposal is to develop potent, selective antagonists for the orphan
receptor GPR17. Ultimately, ligands developed under this application will serve as tools to probe signaling
mechanisms and in vivo functions, and could expedite development of novel therapies for diseases potentially
mediated by GPR17, such as Multiple Sclerosis (MS). MS is a severe neurological disease characterized by
autoimmune-mediated demyelination of neurons and oligodendrocyte damage. The resulting axonal
degeneration impairs rapid nerve conduction, which leads to neurological disability if not repaired through
remyelination. The remyelination process requires proliferation and maturation of oligodendrocyte precursor cells
(OPCs) into myelin producing mature oligodendrocytes. GPR17 is an orphan GPCR that has been identified as
a negative regulator of oligodendrocyte maturation and is predominantly expressed in OPCs. GPR17-/- mice have
increased CNS myelination and GPR17 overexpressing mice showed lack of myelin sheath formation in the
CNS, similar to that seen in myelinating disorders. Addition of the GPR17 agonist probe MDL29,951 to cultures
from GPR17+/- mice resulted in reduced differentiation of oligodendrocytes, along with a decrease in myelin basic
protein (MBP) and dendrite formation. In addition, studies using an MS mouse model (experimental autoimmune
encephalomyelitis, EAE) showed an upregulation of GPR17 in CNS regions where demyelination was occurring.
Collectively, these data suggest the involvement of GPR17 in CNS demyelination upon activation. Hence, novel
small molecule antagonists that can selectively modulate GPR17 functions will be invaluable tools to study
GPR17 biology and lead to new drug discovery opportunities to treat severe demyelinating diseases such as
MS.
To date, very few small molecule antagonists have been reported in the literature and pharmacological
studies with the existing non-selective and less potent antagonists have been challenging. Our preliminary work
led to the identification of a novel small molecule lead compound SN-50 (GPR17 IC50 = 1701 nM, CysLT1, IC50
= 6580 nM) through structural modification of Pranlukast, a non-selective GPR17 antagonist (GPR17 IC50 = 588
nM, CysLT1 IC50 = 4 nM). SN-50 exhibited ~3- and 1600-fold reduced potency at GPR17 and CysLT1
respectively, and is ~4-fold selective for GPR17 over CysLT1. Moreover, SN-50 exhibits ~6-fold improved
selectivity compared to our previous lead SN-23 (GPR17 IC50 = 1035 nM, CysLT1, IC50 = 590 nM), which
promoted oligodendrocyte differentiation upon evaluation in a rat OPC differentiation assay. SN-50 therefore
serves as an excellent lead to identify potent and selective GPR17 antagonists. In Specific Aim 1 of the proposed
R03 project, we will synthesize at least 100 novel SN-50 analogs through a series of iterative scaffold
modifications. In Specific Aim 2, we will evaluate the synthesized compounds for GPR17 potency and selectivity
over CysLT1. Preliminary ADME properties of two lead compounds with favorable antagonist potency and
selectivity (GPR17 IC50 < 100 nM, >50-fold selectivity over CysLT1) will also be evaluated. These Aims will be
accomplished through a collaboration of chemistry and in vitro pharmacology.
项目概述:R 03提案的目标是为孤儿药开发有效的选择性拮抗剂。
GPR 17受体。最终,在此应用下开发的配体将作为探测信号传导的工具
机制和体内功能,并可能加快疾病的新疗法的开发,
由GPR 17介导的疾病,如多发性硬化症(MS)。MS是一种严重的神经系统疾病,
自身免疫介导的神经元脱髓鞘和少突胶质细胞损伤。由此产生的轴突
退化损害快速神经传导,如果不通过修复,
髓鞘再生髓鞘再生过程需要少突胶质前体细胞的增殖和成熟
(OPCs)转化为产生髓鞘的成熟少突胶质细胞。GPR 17是一种孤儿GPCR,已被鉴定为
少突胶质细胞成熟的负调节因子,主要在OPCs中表达。GPR 17-/-小鼠具有
CNS髓鞘形成增加和GPR 17过表达的小鼠显示,在中枢神经系统中缺乏髓鞘形成。
CNS,类似于髓鞘形成疾病中所见。向培养物中添加GPR 17激动剂探针MDL 29,951
结果显示,GPR 17 +/-小鼠的神经胶质细胞分化减少,沿着髓鞘碱性磷酸酶的减少。
蛋白(MBP)和树突形成。此外,使用MS小鼠模型(实验性自身免疫)的研究
脑脊髓炎,EAE)显示在发生脱髓鞘的CNS区域中GPR 17的上调。
总的来说,这些数据表明GPR 17在活化后参与CNS脱髓鞘。因此,小说
可以选择性调节GPR 17功能的小分子拮抗剂将是研究的宝贵工具
GPR 17生物学和导致新药发现的机会,以治疗严重的脱髓鞘疾病,
女士
迄今为止,文献和药理学中报道的小分子拮抗剂很少
对现有的非选择性和效力较低的拮抗剂的研究具有挑战性。我们的前期工作
导致鉴定了新的小分子先导化合物SN-50(GPR 17 IC 50 = 1701 nM,CysLT 1,IC 50
= 6580 nM),通过非选择性GPR 17拮抗剂(GPR 17 IC 50 = 588
nM,CysLT1 IC50 = 4 nM)。SN-50在GPR 17和CysLT 1处表现出约3倍和1600倍的效价降低
并且对GPR 17的选择性是CysLT 1的约4倍。此外,SN-50表现出约6倍的改善,
与我们之前的先导SN-23(GPR 17 IC 50 = 1035 nM,CysLT 1,IC 50 = 590 nM)相比,
在大鼠OPC分化测定中评估时,促进少突胶质细胞分化。SN-50
作为鉴定有效的和选择性的GPR 17拮抗剂的极好的线索。具体目标1:
R 03项目,我们将通过一系列迭代支架合成至少100种新型SN-50类似物
修改.在具体目标2中,我们将评价合成化合物的GPR 17效价和选择性
CysLT 1的具有良好拮抗剂效力的两种先导化合物的初步ADME性质,
还将评估选择性(GPR 17 IC 50 < 100 nM,超过CysLT 1的选择性>50倍)。这些目标将是
通过化学和体外药理学的合作完成。
项目成果
期刊论文数量(0)
专著数量(0)
科研奖励数量(0)
会议论文数量(0)
专利数量(0)
数据更新时间:{{ journalArticles.updateTime }}
{{
item.title }}
{{ item.translation_title }}
- DOI:
{{ item.doi }} - 发表时间:
{{ item.publish_year }} - 期刊:
- 影响因子:{{ item.factor }}
- 作者:
{{ item.authors }} - 通讯作者:
{{ item.author }}
数据更新时间:{{ journalArticles.updateTime }}
{{ item.title }}
- 作者:
{{ item.author }}
数据更新时间:{{ monograph.updateTime }}
{{ item.title }}
- 作者:
{{ item.author }}
数据更新时间:{{ sciAawards.updateTime }}
{{ item.title }}
- 作者:
{{ item.author }}
数据更新时间:{{ conferencePapers.updateTime }}
{{ item.title }}
- 作者:
{{ item.author }}
数据更新时间:{{ patent.updateTime }}
Sanju Narayanan其他文献
Sanju Narayanan的其他文献
{{
item.title }}
{{ item.translation_title }}
- DOI:
{{ item.doi }} - 发表时间:
{{ item.publish_year }} - 期刊:
- 影响因子:{{ item.factor }}
- 作者:
{{ item.authors }} - 通讯作者:
{{ item.author }}
{{ truncateString('Sanju Narayanan', 18)}}的其他基金
Optimization of Small Molecule GPR17 Antagonists for Multiple Sclerosis
多发性硬化症小分子 GPR17 拮抗剂的优化
- 批准号:
10192529 - 财政年份:2021
- 资助金额:
$ 10.97万 - 项目类别:
相似海外基金
Unraveling Adverse Effects of Checkpoint Inhibitors Using iPSC-derived Cardiac Organoids
使用 iPSC 衍生的心脏类器官揭示检查点抑制剂的副作用
- 批准号:
10591918 - 财政年份:2023
- 资助金额:
$ 10.97万 - 项目类别:
Optimization of mRNA-LNP vaccine for attenuating adverse effects and analysis of mechanism behind adverse effects
mRNA-LNP疫苗减轻不良反应的优化及不良反应机制分析
- 批准号:
23K15383 - 财政年份:2023
- 资助金额:
$ 10.97万 - 项目类别:
Grant-in-Aid for Early-Career Scientists
Elucidation of adverse effects of combined exposure to low-dose chemicals in the living environment on allergic diseases and attempts to reduce allergy
阐明生活环境中低剂量化学品联合暴露对过敏性疾病的不良影响并尝试减少过敏
- 批准号:
23H03556 - 财政年份:2023
- 资助金额:
$ 10.97万 - 项目类别:
Grant-in-Aid for Scientific Research (B)
Green tea-based nano-enhancer as an adjuvant for amplified efficacy and reduced adverse effects in anti-angiogenic drug treatments
基于绿茶的纳米增强剂作为抗血管生成药物治疗中增强疗效并减少不良反应的佐剂
- 批准号:
23K17212 - 财政年份:2023
- 资助金额:
$ 10.97万 - 项目类别:
Grant-in-Aid for Early-Career Scientists
Effects of Tobacco Heating System on the male reproductive function and towards to the reduce of the adverse effects.
烟草加热系统对男性生殖功能的影响以及减少不利影响。
- 批准号:
22H03519 - 财政年份:2022
- 资助金额:
$ 10.97万 - 项目类别:
Grant-in-Aid for Scientific Research (B)
Mitigating the Adverse Effects of Ultrafines in Pressure Filtration of Oil Sands Tailings
减轻油砂尾矿压力过滤中超细粉的不利影响
- 批准号:
563657-2021 - 财政年份:2022
- 资助金额:
$ 10.97万 - 项目类别:
Alliance Grants
1/4-Deciphering Mechanisms of ECT Outcomes and Adverse Effects (DECODE)
1/4-破译ECT结果和不良反应的机制(DECODE)
- 批准号:
10521849 - 财政年份:2022
- 资助金额:
$ 10.97万 - 项目类别:
4/4-Deciphering Mechanisms of ECT Outcomes and Adverse Effects (DECODE)
4/4-破译ECT结果和不良反应的机制(DECODE)
- 批准号:
10671022 - 财政年份:2022
- 资助金额:
$ 10.97万 - 项目类别:
2/4 Deciphering Mechanisms of ECT Outcomes and Adverse Effects (DECODE)
2/4 ECT 结果和不良反应的破译机制(DECODE)
- 批准号:
10670918 - 财政年份:2022
- 资助金额:
$ 10.97万 - 项目类别:
Adverse Effects of Using Laser Diagnostics in High-Speed Compressible Flows
在高速可压缩流中使用激光诊断的不利影响
- 批准号:
RGPIN-2018-04753 - 财政年份:2022
- 资助金额:
$ 10.97万 - 项目类别:
Discovery Grants Program - Individual